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Abstract 
Introduction: Neurogenic heterotopic ossification (NHO) is a complication of a neurological 
injury following traumatic brain injury (TBI) and may be present around major synovial joints. 
It is often accompanied by severe pain which may lead to limitation in activities of daily living. 
Currently the only effective treatment for NHO is surgery which carries with it many additional 
risks. This study was designed to assess the effect of extracorporeal shock wave therapy 
(ESWT) on pain in patients with TBI with chronic NHO. 
Methods: A series of single case studies was undertaken on 11 patients with TBI with chronic 
NHO at the hip or knee. Each patient received four applications of high-energy EWST 
delivered to the affected joint over eight weeks. Two-weekly follow-up assessments were 
carried out and final assessments were made three months and six months post-intervention. 
Pain was measured using the Faces Rating Scale (FRS) and X-rays were taken at baseline and 
six-months post-intervention to physiologically measure the size of the NHO. 
Results: The application of high-energy ESWT was associated with overall reduction in pain 
in patients with TBI with NHO (TAU-0.412, 95% CI-0.672 to -0.159, P=0.002).  
Conclusions: ESWT is a novel non-invasive intervention for reducing pain resulting from 
NHO in patients with TBI 
  
 
 
 
 
 
 Case Series ESWT as a treatment for Chronic NHO   
3 
 
Introduction and Background  
Heterotopic ossification (HO) is defined as the formation of mature, lamellar bone inside soft-
tissue structures outside normal skeletal locations [1-3]. Neurogenic heterotopic ossification 
(NHO) is a complication of a neurological injury, with ossification often affecting major 
synovial joints such as the hip or knee [2, 3]. NHO is particularly found in patients following 
traumatic brain injury (TBI), with an estimated prevalence of between 3% and 23% [4-6]. NHO 
typically develops within two to four months of the initial trauma and manifests itself clinically 
as swelling, erythema, warmth, and severe pain [7]. The size of the NHO tends to increase over 
the next few months, and is usually fully developed by one year post-injury when it is reliably 
seen on radiographs [1,8]. The mature NHO may greatly limit activities of daily living thereby 
adversely affecting quality of life of patients with TBI [7, 9-12].  
To date, treatments for NHO have been pharmacological, surgical or a combination of both [13]. 
The pharmacological treatments, however, are not successful once NHO has formed [14]. 
Surgical removal is virtually the only effective treatment for the mature NHO, although it is 
extremely invasive and not possible for all patients following TBI [15]. 
Despite the extensive use of extracorporeal shock wave therapy (ESWT) in the treatment of a 
range of musculoskeletal conditions [16], NHO following TBI has received only limited 
attention [17-20]. The aim of this study was to investigate the effect of ESWT on pain in patients 
following TBI. In addition, the morphology of NHO was also assessed using radiographs. 
Methods 
Ethics approval for this study was granted by the Human Research Ethics Committees of Beit 
Loewenstein Rehabilitation Centre, Israel and James Cook University Townsville, Australia, 
Research ID: 0020-13-LOE. The study was also registered at ClinicalTrials.gov Identifier 
NCT02331628. 
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 Study design 
The study design was an interventional, experimental study. A series of single case research 
studies was undertaken, where participants were assessed on multiple occasions, i.e. pre-, 
during, and post-intervention (Table 1). Four baseline assessments were conducted at two-
weekly intervals prior to intervention. During the four interventions of ESWT, also conducted 
at two weekly intervals, assessments were again performed.  Subsequent to the intervention 
period four further two-weekly follow-up assessments were carried out (Table 1). Final 
assessments were made three months and six months post-intervention (Week 26 and Week 
38; Table 1). This study took place at Beit Lowenstein Hospital, Ra’anana, Israel between 
October 13th 2014 and February 23rd 2016.  
 
Insert Table 1
Participants 
Patients with TBI who met the selection criteria were identified from the database of the Beit 
Loewenstein Rehabilitation Centre, Israel. Eligible participants were aged over 18, with a 
history of TBI and a diagnosis of NHO around the hip or knee for a period of more than one 
year, and a stable serum alkaline phosphatase (SAP) level at the time of recruitment. 
Participants who were pregnant, suffering from rheumatoid arthritis, ankylosing spondylitis or 
femoral/pelvic fractures at the time of recruitment were excluded from the study. Participants 
were contacted by telephone and /or letter and invited to take part in the trial. All participants 
were asked to attend the Beit Loewenstein Rehabilitation Centre and assessed for their 
eligibility by the attending Medical Officer and co-investigator (YS). All participants who met 
the inclusion criteria were asked to sign the consent form.  In those cases where the participants 
had legal guardians and/or were unable to sign, the legal guardian provided informed consent. 
 Case Series ESWT as a treatment for Chronic NHO   
5 
 
Intervention 
The Minispec Extracorporeal Shock Wave instrument (Medispec Int. USA) was used to deliver 
four applications of EWST to the affected hip or knee over a period of eight weeks (one dose 
every two weeks ± 3 days). The patients received 3000 shocks/treatment, with an energy flux 
density (EFD) per shock of 0.176 mJ/mm2. This dosage is considered as high-energy EWST 
according to the Kassel classification (High EFD>0.12mJ/mm2) [21,22].  
Pain was measured using the Faces Rating Scale (FRS) as described elsewhere [23,24]. In 
addition, X-rays and routinely available laboratory data for serum alkaline phosphatase (SAP), 
which is reported to parallel the activity of ossification, were also collected to monitor the 
progression of NHO [25]. Normative values for SAP are 53 - 128 units per litre (U/L) in a 20 to 
50 year-old man and 42 -98 U/L in a 20 to 50 year-old woman.  Adults over 61 years have 
normative values of SAP of 51-153 U/L [26]. 
X-ray analysis 
The NHO size was measured from plain X-rays taken at baseline and at approximately six 
months post-intervention. An X-ray view was set up for each patient and recorded so that it 
could be repeated. The view was not necessarily a standard view; each individual patient had 
their own particular view which was reproducible, dependent on available range of motion and 
pain. Prominent landmarks that were clearly visible on images from both baseline and six 
month post-intervention were selected. The diameter of the ossified lesion was measured at 
one landmark (M1) and, where possible, a second measurement at right angles was also taken 
(M2). Since post-intervention X-ray techniques differed slightly from baseline measure, the 
measurements were standardised using a correction factor calculated from measurements taken 
from a region of normal bone measured at the same place on the pre and post intervention X-
rays.  
 Case Series ESWT as a treatment for Chronic NHO   
6 
 
Qualitative assessments of baseline and six month post-intervention NHO X-rays were 
performed using the Clearcanvas PACS system (Clearcanvas Inc. Toronto ON). The margins 
of the lesions were examined for clarity or fragmentation. Any trabeculation within the ossified 
areas was assessed for increase or decrease in number of the trabeculae; any new bone 
formation or any loss of bone was noted. 
Reporting Adverse Events 
Participants were asked at each assessment if they had any adverse events to report. 
Statistical analysis  
Pain data were assessed from the FRS and were plotted individually and graphically for each 
participant allowing visual inspection of trends within baseline, intervention and post-
intervention phases. The effect size estimates associated with the application of ESWT were 
calculated using the non-parametric non-overlap Tau-U method [27]. The resulting effect size 
estimates were interpreted as the magnitude of intervention effect in percentages. In particular, 
the Tau-U score represents the percentage of non-overlap between phases or the percentage of 
data showing improvement between phases [27]. Higher Tau-U scores signify greater 
effectiveness while lower Tau-U scores denote an intervention that is less effective. The Tau-
U method is designed to control for baseline trend and is the preferred method to estimate effect 
sizes when a positive linear trend in therapeutic direction exists in baseline [27]. All Tau-U score 
computations were performed using the Tau-U Calculator (Single Case Research™, USA).  
X-Ray measurements were compared between post-intervention phase and baseline phase 
using the Wilcoxon signed-rank test. All computations were performed using the Stata MP/13 
statistical package (StataCorp LP, USA).  
Statistical significance was defined at the conventional 5% level. 
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Results 
Patient Characteristics 
Eleven patients with TBI were recruited; 4 patients presented with NHO in the affected knee 
and 7 in the affected hip (Table 2). Six of the 11 patients were ambulant (with or without an 
aid) (Table 2). TBI patients were less likely to be females (2/11; 18%), were of relatively young 
age (mean age 41±14 years), and had BMI scores of 25±4 kg/m2 (Table 2). NHO tended to 
occur equally on both sides; 5 patients had their right affected side treated and 6 were treated 
on their left side (Table 2). Ten out of the 11 patients recruited were noted to have constant 
pain intensity on the FRS varying between 5 and 10. All participants presented with varying 
degrees of functional and mobility dysfunction (FIM motor score between 13 and 86; Table 2). 
Two participants (Cases #4 and #9) completed the four baseline measures and the four 
interventions and immediate post-intervention measures but were then lost to follow-up. 
Circulating SAP levels remained stable within normal limits in all patients with TBI who 
completed the full trial (Table 2). None of the participants were considered suitable at this time 
for surgical intervention; two of the patients recruited had had surgery several years earlier (one 
at the knee and one at the hip) but the NHO had regrown. 
 
Insert Table 2 
Effect of ESWT on Pain (FRS) 
Nine patients completed the baseline, intervention phase, the post-intervention phase and the 
three and six month follow-up. Visual inspection of individual FRS pain results during the 
post-intervention phase, showed a reduction in FRS scores relative to the baseline phase in four 
patients with TBI (cases 1, 2, 3, and 6; Figure 1). Visual inspection of cases 5, 7, 8, and 10 
individual results was not informative (Figure 1). There was no pain reported in case 11 during 
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the trial, and cases 4 and 9 did not complete the post-intervention phase (Figure 1). Overall Tau 
score shows that ESWT was associated with significant reduction of FRS Pain score in TBI 
patients post-intervention compared to the baseline (Tau-0.415, 95% CI -0.672 to -0.159, 
P=0.002; Table 3). 
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Insert Figure 1 
Insert Table 3 
 Effect of ESWT on NHO as seen on Plain X-ray film 
Nine of the 11 participants completed the full study, including repeat X-rays, taken at least 6 
months post intervention. Three of the nine patients who completed had only one NHO 
diameter measurement (M1) taken due to the fact that the areas of NHO were too large and ill-
defined to allow an accurate second measure to be taken.  Overall, the smallest and the largest 
NHO diameters at baseline and at 6 month post-intervention were similar and showed no 
significant difference in all patients with TBI (P>0.05; Table 4).  
 
Insert Table 4 
 
Qualitative description of X-rays 
Post-intervention X-rays showed erosion in the margin of the ossified areas and slight 
fragmentation of the lesion compared to the baseline radiographs (Figure 2). In addition, the 
clarity of the borders and loss of the "cortex" of the lesion could be seen (Figure 2).  
Insert Figure 2 
Pre- and post-radiographs of all nine participants who completed the trial are provided in the 
Supplementary Data. 
Adverse effects 
Minor adverse effects of a transient slight increase in pain immediately following treatment 
were reported in two cases.  
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Discussion 
This study reports a reduction of pain associated with the use of ESWT in patients following 
TBI with NHO. The results substantiate those of our previously published case report [19]. Our 
earlier and current results collectively demonstrate the importance of the single case research 
design in populations with disabling conditions such as NHO. Although we found an overall 
reduction in pain using ESWT, by focusing on individual patients with TBI and undertaking 
multiple measurements during the study, we were able to track their responses over time. This 
is an advantage over a randomised controlled trial design where group results only tend to be 
reported, and it is difficult to determine those individuals for whom a treatment may be 
effective or even be shown to worsen the condition. In this context, two individuals did not 
report pain associated with their NHO; in these participants reduced range of movement was 
the main effect of NHO (see companion paper).  The application of ESWT was associated with 
a transient increase of pain post-intervention in two participants; no other participants reported 
an increase of pain post-intervention.  
The pain presentation within the patients with TBI was variable. Some participants complained 
of pain only when performing a functional activity, others complained of pain only on passive 
movement of the affected joint and some complained of intractable pain throughout the day, 
suggesting the involvement of nociceptive and neuropathic mechanisms, respectively [28-30]. In 
this study we focussed on the pain intensity rather than the pain quality. It is doubtful that this 
particular patient group with TBI would have been able to provide valid descriptors of their 
pain since this patient group often presents with various non-compliance concerns such as 
cognitive problems, aggressive tendencies or impulsivity, forgetfulness, and apathy [31].  
We also demonstrated erosion and marginal absorption around the NHO deposits at six month 
post-intervention; however, this was not associated with detectable overall changes in the size 
of NHO using radiographs. Thus it is reasonable to suggest that reduction of pain was 
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associated with mechanisms other than a simple reduction in NHO size, triggered by ESWT. 
It has been suggested that the application of ESWT may have an effect on gene expression, 
including upregulation of anti-inflammatory cytokines [32]. There is growing evidence that 
cytokines play an important role in mediating pain in neuropathic conditions, including 
suppression of pain associated with the systemic administration of the anti-inflammatory 
interleukin (IL)-10 cytokine in animal models [33-35]. It is possible that ESWT may have 
impacted on the production of anti-inflammatory cytokines which led to the observed reduction 
in pain. However further investigation is needed regarding the role of ESWT and cytokine 
production in patients with TBI. 
Limitations of this study include a relatively small number of participants and of females in 
particular. Although the male: female ratio is consistent with that commonly found within this 
patient population, the small number of women does limit the generalizability of this study. 
Furthermore, it is important to note that only nine of the 11 patients completed the full trial. 
Further limitations include the relatively low clarity of the radiographic evidence, making it 
difficult to reliably assess quantitative changes associated with the application of ESWT in the 
mature NHO.  Other imaging techniques may be necessary to assess the NHO quantitatively. 
This study was conducted as a series of single case research studies that allows us to draw 
conclusions about the effects of a specific treatment based upon the responses of single patients 
[36]. No “sham” trial was considered feasible with this patient group that commonly presents 
with a profound cognitive impairment [31] but the study design was such that each patient 
became their own control for the purpose of comparison [37]. 
 
Conclusions 
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The results of this study highlight a role for ESWT in reducing pain in patients with TBI with 
NHO and warrant its further investigation as a therapeutic approach that could be of potential 
clinical benefit. 
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Table 1:  
Timeline of outcome measures collected during this study.  
Baseline  Intervention phase 
(ESWT) 
 Follow-up 
Weeks  Weeks  Weeks 
 0  2  4  6  8  10  12 14  16  18 20 22 26   38 
FRS FRS FRS FRS  FRS FRS FRS FRS  FRS FRS FRS FRS FRS FRS 
SAP 
level 
     SAP 
level 
      SAP 
level 
  
X-ray               X-ray 
 
ESWT, extracorporeal shockwave treatment; FRS, Faces Rating Scale; SAP, serum alkaline phosphatase 
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Table 2: Characteristics of patients included in this study. 
Case Gender Age 
(years) 
Weight 
(kg) 
Height 
(cm) 
BMI 
(kg/m2) 
FIM SAP (U/L) Affected joint Walking Pain 
medication 
before trial B I PI 
1 m 53 85 171 29 79 79 96 96 left hip yes No 
2 m 52 85 175 28 66 72 72 57 right knee yes with cane No 
3 m 21 60 167 21 83 112 98 n/a left knee yes with cane No 
Ϯ4 m 57 78 174 26 75 107 107 80 left knee yes No 
5 m 26 68 168 24 56 156 167 128 left hip no No 
6 m 62 95 173 32 86 95 98 117 right hip yes No 
7 m 47 74 194 20 51 149 150 165 right hip no *Yes 
8 f 23 58 171 20 73 53 n/a n/a right hip yes with crutches No 
Ϯ9 m 35 75 185 22 25 108 111 n/a right hip no No 
10 f 44 63 166 23 13 n/a n/a n/a left hip no *Yes 
11 m 36 85 189 29 37 115 115 n/a left knee no No 
Mean - 41±14 75±12 176±9 25±4 - - - - - - - 
U/L, units per litre; m, male; f, female; FIM, functional independence measure; FIM motor scores range from 13 (total dependence) to 91 (total independence). 
*Pain medication ceased post-intervention  Ϯ Cases #4 and #9 did not complete post intervention assessments  
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Table 3:  Effect of ESWT on Pain (FRS). 
Patient 
Baseline vs *Intervention Baseline vs Post-intervention 
Tau CI 95% P Tau CI 95% P 
1 -0.250 -1.099 to 0.599 0.564 -0.375 -1.141 to 0.391 0.337 
2 0.000 -0.849 to 0.849 1.000 -0.333 -1.099 to 0.433 0.394 
3 0.500 -0.349 to 1.349 0.248 -0.667 -1.433 to 0.099 0.088 
4 -0.250 -1.099 to 0.599 0.564 Lost to follow-up 
5 -0.500 -1.349 to 0.349 0.248 -0.500 -1.266 to 0.266 0.201 
6 -1.000 -1.849 to -0.151 0.021 -0.917 -1.683 to -0.151 0.019 
7 0.750 -0.099 to 1.599 0.083 -0.125 -0.891 to 0.641 0.749 
8 0.583 -0.341 to 1.507 0.216 -0.100 -0.900 to 0.700 0.807 
9 -1.000 -1.849 to -0.151 0.021 Lost to follow-up 
10 -0.500 -1.349 to 0.349 0.248 -0.708 -1.474 to 0.058 0.070 
11 0.000 -0.849 to 0.849 1.000 0.000 -0.766 to 0.766 1.000 
Overall -0.157 -0.415 to 0.101 0.233 -0.415 -0.672 to -0.159 0.002 
 
*During the intervention phase pain intensity was recorded after the application of ESWT  
Tau, Tau scores; CI 95%, 95% confidence interval; P, P-value 
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Table 4: Quantitative assessment of NHO using X-ray-based measurements. 
Case Largest NHO diameter measures (mm) Smallest NHO diameter measures (mm) 
Baseline Post-intervention D% Baseline Post-intervention D% 
M1 M2 M1 M2 M1 M2 M1 M2 M1 M2 M1 M2 
1 168.0 40.7 134.4 30.3 -20.0 -25.7 49.0 17.0 43.7 17.3 -9.9 1.0 
2 83.0 22.8 83.0 24.9 0.0 9.2 11.0 10.0 12.8 10.6 12.3 3.9 
3 174.0 20.2 149.5 20.1 -14.3 -0.5 55.0 34.0 53.8 31.4 -2.7 -8.5 
5 102.0 53.5 94.3 62.4 -7.8 16.6 102.0 67.0 94.3 65.9 -7.5 -1.2 
6 114.0 69.3 113.8 71.9 0.1 3.8 29.0 10.0 28.6 10.6 -2.1 1.9 
7 102.0 16.1 104.6 16.7 2.6 3.7 54.0 18.0 52.4 21.3 -3.7 19.0 
8 31.1 5.9 33.7 6.5 8.2 10.7 No second measure possible 
10 83.6 138.0 87.5 79.0 4.7 -42.9 No second measure possible 
11 40.9 4.3 37.2 4.85 -9.0 12.8 No second measure possible 
P - - 0.86 0.93 - - - - 0.71 0.75 - - 
 
M1, measurement 1 (largest or smallest NHO diameter); M2, measurement 2 (taken at right angles to M1); P, P-value paired Wilcoxon signed-
rank test; D%, percent difference between respective post-intervention and baseline M 1 and M2 
§ M1 and M2 values post intervention are the corrected values (refer to Methods).  
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Figure 1: Effect of ESWT on Pain (FRS).  
Pain intensity was recorded after the application of ESWT during the intervention phase. 
Horizontal axes, time in weeks (time points are not proportional); Weeks 0 to 6, baseline phase; 
Weeks 8 to 14, intervention phase; Weeks 16 to 38, post-intervention phase; Vertical axes, FRS 
Pain scores. (Patient#11 FRS score 0 throughout) 
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Reznik et al. Supplementary data 
Individual Commentaries (provided by an independent radiologist): 
Case #1: No qualitative changes detected; no erosions or loss of bone (Plate 1). 
 
Plate 1: Baseline and post-intervention X-rays.  
Case #2: Post- intervention X-rays showed erosion in the margin of the ossified areas and slight 
fragmentation of the lesion. In addition of clarity of the borders and loss of the cortex of the 
lesion could be seen (Plate 2).  
 
Plate 2: Baseline and post-intervention X-rays.  
Alteration in 
the margin of 
ossification  
Reduction of 
overhanging 
bone 
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Case #3: The visual impression was that the lesion had increased in size between the two 
studies (Plate 3). 
 
Plate 3: Baseline and post-intervention X-rays. 
Case #5: Very similar techniques for both baseline and post-intervention X-rays. A definite 
irregularity of the upper border of the lesion under the femoral neck on the post intervention 
X-ray was noted. Lower border of the lesion was fragmented suggesting possible erosion of 
the lesion (Plate 5). 
 
Plate 5: Baseline and post-intervention X-rays.  
Apparent 
increase in 
area of 
bone  
Irregularity at the 
upper border of 
the lesion 
Fragmentation at 
the lower border 
of the lesion 
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Case #6: On subjective assessment there appeared to be some erosion of the lesion on the post 
intervention study. (Plate 6) 
 
Plate 6: Base-line and post-intervention X-rays.  
Case # 7:  On the post-intervention (PI) study of the right hip the margins of the lesions were 
definitely less well defined inferiorly and around the femoral neck. This was also the case 
around the inferior margin of the gluteal ossification. This is of interest because the technical 
differences of the PI study give the image more contrast and a higher definition of the areas 
mentioned than would have been expected. (Plate 7). 
 
Plate 7: Baseline and post-intervention X-rays.  
 
Margins of the 
lesions are less well-
defined inferiorly 
and around the 
femoral neck and 
the inferior margin 
of the gluteal 
ifi ti   
Slight erosive 
changes in the 
PI study 
around the 
lesion 
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Case # 8:  No qualitative changes between the two images were noted (Plate 8). 
 
Plate 8: Baseline and post-intervention X-rays.  
Case#10: A big difference in apparent ossification between the two studies. This apparent ossification 
was most probably due to technical factors, most likely of which was different exposures (Plate 10). 
 
     Plate 10: Baseline and post-intervention X-rays. 
 
Case #11: The spike of bone appeared significantly less dense than previously, although this could be 
a technical radiographic factor (Plate 11).   
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                Plate 11: Baseline and post-intervention X-rays. 
 
 
Treated area, which 
appears less dense 
post-intervention 
